drugset / Trial / NCT06570434
Phase 1b/2a in SLE With Budoputug
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of the study is to determine the safety, tolerability, and pharmacokinetics of budoprutug in participants with SLE
Timeline
- Start
- 2025-01
- Primary completion
- 2026-12
- Completion
- 2027-04
Outcome
Outcome not reported
Stopped: “Study was never initiated”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Budoprutug | Monoclonal antibody | — | — |